Thomas P O'Brien

US Patent:

7618783, Nov 17, 2009

Filed:

Apr 30, 2001

Appl. No.:

09/844281

Inventors:

Beverly Lynn Mangold - Rockville MD, US
Jennifer Lynn Aldrich - Silver Spring MD, US
Thomas W. O'Brien - Fairfax VA, US

Assignee:

Tetracore, Inc. - Rockville MD

International Classification:

G01N 33/53

US Classification:

435 71, 435 4, 435 72, 435 732, 435 772, 435975, 5303871, 5303881, 5303882, 5303884, 4241641

Abstract:

The present invention is directed to diagnostic tools and therapies using antibodies to Specifically, the present invention is directed to a -specific monoclonal antibody that binds to the EA1 antigen (corresponding to the eag gene) of the S-layer (surface layer) of spores. This monoclonal antibody may be used in a variety of applications, including to specifically detect and diagnose Preferably, antibodies are monoclonal and bind to a surface protein, such as EA1 protein, on the spores of and not to spores of either or Antibodies can be incorporated into detection kits using, for example, colloidal particle based lateral flow detection system. Such detection kits can distinguish anthrax spores from non-pathogenic varieties of spores. In addition, the invention is directed to EA1 antigen and pharmaceuticals such as vaccines that can be used as therapeutics and to develop improved antibodies and detection methods.

US Patent:

20110200614, Aug 18, 2011

Filed:

Nov 16, 2009

Appl. No.:

12/619489

Inventors:

Beverly Lynn Mangold - Rockville MD, US
Jennifer Lynn Aldrich - Silver Spring MD, US
Thomas W. O'Brien - Fairfax VA, US

International Classification:

A61K 39/395
C12N 5/071
G01N 33/569
G01N 33/566
C07K 16/12
C12P 21/08
C07K 14/32
A61K 39/07
A61P 37/04
A61P 31/04

US Classification:

4241641, 435340, 435 71, 436501, 5303884, 435 7021, 5303879, 5303873, 5303895, 530350, 4242461

Abstract:

The present invention is directed to diagnostic tools and therapies using antibodies to . Specifically, the present invention is directed to a -specific monoclonal antibody that binds to the EA1 antigen (corresponding to the eag gene) of the S-layer (surface layer) of spores. This monoclonal antibody may be used in a variety of applications, including to specifically detect and diagnose . Preferably, antibodies are monoclonal and bind to a surface protein, such as EA1 protein, on the spores of , and not to spores of either or . Antibodies can be incorporated into detection kits using, for example, colloidal particle based lateral flow detection system. Such detection kits can distinguish anthrax spores from non-pathogenic varieties of spores. In addition, the invention is directed to EA1 antigen and pharmaceuticals such as vaccines that can be used as therapeutics and to develop improved antibodies and detection methods.

US Patent:

20200292546, Sep 17, 2020

Filed:

Jan 24, 2020

Appl. No.:

16/752105

Inventors:

- Bethesda MD, US
Thomas R. O'BRIEN - Potomac MD, US
Brian MUCHMORE - Potomac MD, US
Raymond P. DONNELLY - Damascus MD, US
Patricia A. PORTER-GILL - Little Rock AR, US

International Classification:

G01N 33/569
C07K 14/555
C07K 16/24
C12Q 1/6883

Abstract:

The invention is related to identification of an interferon-analog (IFNL4) protein and genetic association with spontaneous clearance of HCV infection and response to treatment for HCV infection.

US Patent:

20170254808, Sep 7, 2017

Filed:

May 17, 2017

Appl. No.:

15/597459

Inventors:

- Bethesda MD, US
Thomas R. O'BRIEN - Potomac MD, US
Brian MUCHMORE - Potomac MD, US
Raymond P. DONNELLY - Damascus MD, US
Patricia A. PORTER-GILL - Little Rock AR, US

International Classification:

G01N 33/569
C07K 16/24
C12Q 1/68
C07K 14/555

Abstract:

The invention is related to identification of an interferon-analog (IFNL4) protein and genetic association with spontaneous clearance of HCV infection and response to treatment for HCV infection.

US Patent:

20150050640, Feb 19, 2015

Filed:

Mar 14, 2013

Appl. No.:

14/388293

Inventors:

- Bethesda MD, US
Thomas R. O'Brien - Potomac MD, US
Brian Muchmore - Potomac MD, US
Raymond P. Donnelly - Damascus MD, US
Patricia A. Porter-Gill - Little Rock AR, US

International Classification:

G01N 33/569
C07K 16/24
C07K 14/555

US Classification:

435 5, 530324, 530350, 5303879, 536 235, 4353201

Abstract:

The invention is related to identification of an interferon-analog (IFNL4) protein and genetic association with spontaneous clearance of HCV infection and response to treatment for HCV infection.

US Patent:

20140271542, Sep 18, 2014

Filed:

Oct 5, 2012

Appl. No.:

14/349395

Inventors:

- Bethesda MD, US
Thomas O'Brien - Potomac MD, US
Brian Muchmore - Potomac MD, US
Raymond Donnelly - Damascus MD, US

International Classification:

C12Q 1/70

US Classification:

424 854, 435 5, 514 43

Abstract:

The present invention provides methods and materials for predicting the clinical outcome of a hepatitis C virus (HCV) infection. In particular, the invention relates to methods and materials for predicating the ability of an individual to spontaneously clear a hepatitis C virus infection. It also relates to methods and materials useful for predicting the clinical response of an individual suffering from HCV infection to administration of a therapeutic treatment. Also provided are kits for predicting the ability of an individual to spontaneously clear an HCV infection, or spontaneously clear such an infection. The methods and rated kits disclosed herein can also be used to develop a treatment plan for an individual infected with HCV, or who is at risk for developing such an infection.